Short Interest in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Expands By 12.5%

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) was the target of a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 6,680,000 shares, an increase of 12.5% from the December 15th total of 5,940,000 shares. Based on an average daily volume of 975,100 shares, the days-to-cover ratio is presently 6.9 days.

Catalyst Pharmaceuticals Stock Performance

Catalyst Pharmaceuticals stock traded up $0.12 during midday trading on Friday, reaching $22.78. 4,930,123 shares of the stock were exchanged, compared to its average volume of 888,541. The company’s fifty day moving average is $21.75 and its 200-day moving average is $20.27. The firm has a market cap of $2.72 billion, a PE ratio of 19.31, a PEG ratio of 2.16 and a beta of 0.79. Catalyst Pharmaceuticals has a 52 week low of $13.12 and a 52 week high of $24.27.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Bank of America reissued a “buy” rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. StockNews.com lowered shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 11th. HC Wainwright boosted their price target on shares of Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, January 10th. Truist Financial boosted their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, November 11th. Finally, Stephens assumed coverage on shares of Catalyst Pharmaceuticals in a research report on Monday, November 18th. They issued an “overweight” rating and a $35.00 price target on the stock. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $32.86.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Steve Miller sold 50,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total value of $1,096,500.00. Following the sale, the insider now owns 686,996 shares of the company’s stock, valued at approximately $15,065,822.28. The trade was a 6.78 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Molly Harper sold 17,500 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total transaction of $385,000.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 79,500 shares of company stock worth $1,754,140. 11.00% of the stock is owned by insiders.

Institutional Trading of Catalyst Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC grew its stake in Catalyst Pharmaceuticals by 62.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 681 shares in the last quarter. nVerses Capital LLC purchased a new position in Catalyst Pharmaceuticals in the 3rd quarter worth approximately $50,000. Larson Financial Group LLC grew its stake in Catalyst Pharmaceuticals by 27,218.2% in the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 2,994 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. purchased a new position in Catalyst Pharmaceuticals in the 4th quarter worth approximately $134,000. Finally, Quantbot Technologies LP purchased a new position in Catalyst Pharmaceuticals in the 3rd quarter worth approximately $151,000. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.